Skip to content

US · ODTX · BIOTECHNOLOGY

Odyssey Therapeutics, Inc. (ODTX) intrinsic value and stock valuation

$16.96as of 2026-11-21 · Mkt cap 639.94M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Odyssey Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values ODTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ODTX’s statements →

Odyssey Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02210 odysseytx.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$2.98M
20252025
Net income
-$-148.65M
20252025
Free cash flow
-$-130.7M
20252025
Total equity
-$-488.28M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$2.98M
Operating income-$-161.16M
Net income-$-148.65M
EPSd-$-5.39M
Operating cash flow-$-129.47M
Capital expenditure-$-1.23M
Free cash flow-$-130.7M
Total assets$269.8M
Total debt$27.1M
Net debt-$-14.58M
Total equity-$-488.28M
Cash and short-term investments$181.4M
Income statement
2025
Revenue$2.98M
Cost of revenue$0.00
Gross profit$2.98M
Research and development expenses$126.6M
Selling, general and administrative expenses$37.5M
Other expenses$0.00
Operating expenses$164.1M
Cost and expenses$164.1M
Interest income$6.35M
Interest expense$20K
Depreciation and amortization$4.91M
Ebitda-$-144.65M
Operating income-$-161.16M
Total other income/expenses, net$11.6M
Income before tax-$-149.57M
Income tax expense-$-930K
Net income-$-148.65M
Weighted average shares outstanding$27.6M
Weighted average diluted shares outstanding$27.6M
Balance sheet
2025
Cash and short-term investments$181.4M
Net receivables$0.00
Inventory$0.00
Total current assets$190.7M
Property, plant and equipment, net$26M
Goodwill and intangible assets$14.6M
Long-term investments$35.2M
Total non-current assets$79.1M
Total assets$269.8M
Accounts payable$7.87M
Short-term debt$5.21M
Deferred revenue$0.00
Total current liabilities$26.5M
Long-term debt$21.9M
Deferred revenue, non-current$0.00
Total non-current liabilities$731.6M
Capital lease obligations$27.1M
Total liabilities$758.1M
Common stock$0.00
Retained earnings-$-568.14M
Accumulated other comprehensive income (loss)$240K
Total equity-$-488.28M
Total investments$174.9M
Total debt$27.1M
Net debt-$-14.58M
Cash flow statement
2025
Net income-$-148.65M
Depreciation and amortization$4.91M
Stock-based compensation$14.3M
Change in working capital-$-4.73M
Accounts receivable$0.00
Inventory$0.00
Accounts payable$2.06M
Net cash provided by operating activities-$-129.47M
Investments in property, plant and equipment-$-1.23M
Acquisitions, net$0.00
Net cash used for investing activities-$-103.94M
Common stock issued$3.19M
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$215.7M
Net change in cash-$-17.45M
Cash at end of period$44.9M
Operating cash flow-$-129.47M
Capital expenditure-$-1.23M
Free cash flow-$-130.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Odyssey Therapeutics, Inc.

        Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

        CEO
        Gary D. Glick
        Employees
        100
        Beta
        1.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Odyssey Therapeutics, Inc. (ODTX)?

        InvestorsCraft does not currently publish an intrinsic value for ODTX. How the IC value is calculated.

        Is ODTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ODTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.